NITROGLYCERIN IN 5% DEXTROSE INJ.-200MCG/ML 5 G / 100 ML — DIN 02145308
DEXTROSE : 5 G / 100 ML NITROGLYCERIN : 20 MG / 100 ML · BAXTER CORPORATION · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is NITROGLYCERIN IN 5% DEXTROSE INJ.-200MCG/ML?
NITROGLYCERIN IN 5% DEXTROSE INJ.-200MCG/ML 5 G / 100 ML contains DEXTROSE : 5 G / 100 ML NITROGLYCERIN : 20 MG / 100 ML. It is listed in the Health Canada Drug Product Database under DIN 02145308, held by BAXTER CORPORATION, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 31-Dec-1995. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is NITROGLYCERIN IN 5% DEXTROSE INJ.-200MCG/ML used for?
Perioperative hypertension; congestive heart failure in acute MI; treatment of angina pectoris; induction of controlled hypotension during surgery.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Glyceryl Trinitrate in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
20 holders have a Canadian DIN containing Glyceryl Trinitrate, across 39 DINs, of which 18 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| MYLAN PHARMACEUTICALS ULC | 5 | 4 | MYLAN-NITRO PATCH 0.2, MYLAN-NITRO PATCH 0.4, MYLAN-NITRO PATCH 0.6, MYLAN-NITRO PATCH 0.8, MYLAN-NITRO SUBLINGUAL SPRAY | Sourceable in Canada |
| USPHARMA LTD | 4 | 4 | NITRO-DUR 0.2, NITRO-DUR 0.4, NITRO-DUR 0.6, NITRO-DUR 0.8 | Sourceable in Canada |
| ENDO OPERATIONS LTD. | 3 | 3 | TRINIPATCH 0.2, TRINIPATCH 0.4, TRINIPATCH 0.6 | Sourceable in Canada |
| BAXTER CORPORATION | 3 | 2 | NITROGLYCERIN IN 5% DEXTROSE INJ.-100MCG/ML, NITROGLYCERIN IN 5% DEXTROSE INJ.-200MCG/ML, NITROGLYCERIN IN 5% DEXTROSE INJ.-400MCG/ML | Sourceable in Canada |
| BGP PHARMA ULC | 2 | 2 | NITROSTAT | Sourceable in Canada |
| OMEGA LABORATORIES LIMITED | 2 | 1 | NITROJECT, NITROJECT INJ 1MG/ML | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 2 | 1 | NITROGLYCERIN INJECTION USP, RHO-NITRO PUMPSPRAY | Sourceable in Canada |
| SANOFI-AVENTIS CANADA INC | 1 | 1 | NITROLINGUAL PUMPSPRAY | Sourceable in Canada |
| NOVARTIS PHARMACEUTICALS CANADA INC | 4 | 0 | TRANSDERM-NITRO 0.2, TRANSDERM-NITRO 0.4, TRANSDERM-NITRO 0.6, TRANSDERM-NITRO 0.8 | No marketed DIN |
| VALEANT CANADA LP / VALEANT CANADA S.E.C. | 3 | 0 | MINITRAN | No marketed DIN |
| ASTRA PHARMA INC. | 1 | 0 | NITROGARD-SR TAB 1MG | No marketed DIN |
| METRO PHARM INC. | 1 | 0 | NITRONG SR SRT 2.6MG | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 5 G / 100 ML |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | 250 mL glass bottles. |
| Storage | Store between 15 and 25 degrees C. Protect from light and freezing. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Glyceryl Trinitrate |
|---|---|
| ATC code | C01DA02 |
| AHFS class | 24:12.08 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02145308 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2145308 |
| Brand name | NITROGLYCERIN IN 5% DEXTROSE INJ.-200MCG/ML |
| Generic / active ingredient | DEXTROSE : 5 G / 100 ML NITROGLYCERIN : 20 MG / 100 ML |
| Market authorization holder | BAXTER CORPORATION |
| Health Canada schedule | Ethical |
| ATC code | C01DA02 |
| ATC anatomical main group | C — Cardiovascular system |
| ATC therapeutic subgroup | C01DA |
| Current status | MARKETED |
| Status date | 31-Dec-1995 |
| Original market date | 1995-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
IV infusion only via pump. Initial adult dose: 5 mcg/min (non-adsorptive tubing). Titrate in 5 mcg/min increments every 3-5 mins based on response. Continuous BP and HR monitoring required.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to organic nitrates; use of PDE inhibitors (sildenafil, tadalafil, vardenafil) or riociguat; hypotension; uncorrected hypovolemia; increased intracranial pressure; corn allergy.
Warnings and precautions
Nitroglycerin adsorbs to PVC tubing; use non-adsorptive sets. Risk of fluid overload, hyperglycemia (dextrose content), and severe hypotension/shock. Avoid in hereditary fructose intolerance.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
18 of 39 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| MYLAN-NITRO PATCH 0.2 | 0.2 MG | PATCH (EXTENDED RELEASE) | MYLAN PHARMACEUTICALS ULC | MARKETED | 02407442 |
| MYLAN-NITRO PATCH 0.4 | 0.4 MG | PATCH (EXTENDED RELEASE) | MYLAN PHARMACEUTICALS ULC | MARKETED | 02407450 |
| MYLAN-NITRO PATCH 0.6 | 0.6 MG | PATCH (EXTENDED RELEASE) | MYLAN PHARMACEUTICALS ULC | MARKETED | 02407469 |
| MYLAN-NITRO PATCH 0.8 | 0.8 MG | PATCH (EXTENDED RELEASE) | MYLAN PHARMACEUTICALS ULC | MARKETED | 02407477 |
| NITRO-DUR 0.2 | 0.2 MG | PATCH (EXTENDED RELEASE) | USPHARMA LTD | MARKETED | 01911910 |
| NITRO-DUR 0.4 | 0.4 MG | PATCH (EXTENDED RELEASE) | USPHARMA LTD | MARKETED | 01911902 |
| NITRO-DUR 0.6 | 0.6 MG | PATCH (EXTENDED RELEASE) | USPHARMA LTD | MARKETED | 01911929 |
| NITRO-DUR 0.8 | 0.8 MG | PATCH (EXTENDED RELEASE) | USPHARMA LTD | MARKETED | 02011271 |
| NITROGLYCERIN IN 5% DEXTROSE INJ.-400MCG/ML | 5 G / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | 02145316 |
| NITROJECT | 50 MG / 10 ML | SOLUTION | OMEGA LABORATORIES LIMITED | MARKETED | 00778869 |
2 · Same class — other molecules in ATC C01DA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Glyceryl Trinitrate | APO-NITROGLYCERIN · MINITRAN · MINITRAN - PATCH TRD 72MG/26.6 SQ CM · MYLAN-NITRO PATCH 0.2 · +31 more | 39 | 18 | Yes |
| Isosorbide Mononitrate | APO-ISMN · DOM-ISMN · IMDUR · ISMN · +4 more | 8 | 3 | Yes |
| Isosorbide Dinitrate | CEDOCARD-SR SRT 20MG · CEDOCARD-SR SRT 40MG · CORADUR TAB 20MG · CORONEX · +16 more | 25 | 2 | Yes |
| Pentaerithrityl Tetranitrate | PERITRATE SA 80MG TAB · PERITRATE TAB 10MG · PERITRATE TAB 20MG | 3 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC C01D
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| C01DX | Nesiritide · Vericiguat | 4 | 3 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Request a quote for NITROGLYCERIN IN 5% DEXTROSE INJ.-200MCG/ML
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.